Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
deaths (OS) | 0.99 [0.86, 1.15] | | < 1 | | 0% | 3 studies (3/-) | 53.5 % | some concern | not evaluable | moderate | crucial | - |
progression or deaths (PFS) | 1.06 [0.71, 1.57] | | < 1 | | 83% | 3 studies (3/-) | 39.0 % | some concern | not evaluable | moderate | important | - |
DCR | 2.37 [1.73, 3.25] | | > 1 | | 12% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
objective responses (ORR) | 1.81 [0.94, 3.50] | | > 1 | | 41% | 3 studies (3/-) | 96.2 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
TRAE (any grade) | 0.45 [0.26, 0.76] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) | 0.83 [0.21, 3.29] | | < 1 | | 94% | 2 studies (2/-) | 60.5 % | some concern | not evaluable | moderate | non important | - |
TRAE leading to death (grade 5) | 0.72 [0.08, 6.23] | | < 1 | | 0% | 2 studies (2/-) | 61.5 % | some concern | not evaluable | moderate | non important | - |
TRAE leading to discontinuation (any grade) | 0.72 [0.40, 1.33] | | < 1 | | 0% | 2 studies (2/-) | 85.2 % | some concern | not evaluable | moderate | non important | - |
TRAE (grade 3-4) endpoints 00 |
Abdominal pain TRAE (grade 3-4) | 0.73 [0.08, 6.26] | | < 1 | | 0% | 2 studies (2/-) | 61.3 % | some concern | not evaluable | moderate | non important | - |
Acute kidney injury TRAE (grade 3-4) | 1.42 [0.11, 18.62] | | < 1 | | 0% | 2 studies (2/-) | 39.4 % | some concern | not evaluable | moderate | non important | - |
Adrenal insufficiency TRAE (grade 3-4) | 1.29 [0.15, 11.04] | | < 1 | | 0% | 3 studies (3/-) | 41.0 % | some concern | not evaluable | moderate | non important | - |
Anaemia TRAE (grade 3-4) | 0.48 [0.21, 1.09] | | < 1 | | 0% | 2 studies (2/-) | 96.0 % | some concern | not evaluable | moderate | non important | - |
Asthenia TRAE (grade 3-4) | 2.06 [0.30, 14.08] | | < 1 | | 5% | 2 studies (2/-) | 23.1 % | some concern | not evaluable | moderate | non important | - |
Blood creatinine increased TRAE (grade 3-4) | 1.42 [0.11, 18.62] | | < 1 | | 0% | 2 studies (2/-) | 39.4 % | some concern | not evaluable | moderate | non important | - |
Colitis TRAE (grade 3-4) | 2.14 [0.54, 8.54] | | < 1 | | 0% | 3 studies (3/-) | 14.2 % | low | not evaluable | high | non important | - |
Constipation TRAE (grade 3-4) | 0.96 [0.06, 15.40] | | < 1 | | 0% | 2 studies (2/-) | 51.2 % | some concern | not evaluable | moderate | non important | - |
Decreased appetite TRAE (grade 3-4) | 1.43 [0.11, 18.70] | | < 1 | | 0% | 2 studies (2/-) | 39.3 % | some concern | not evaluable | moderate | non important | - |
Diabetes TRAE (grade 3-4) | 2.01 [0.07, 59.96] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
Diarrhoea TRAE (grade 3-4) | 4.92 [0.54, 44.97] | | < 1 | | 0% | 2 studies (2/-) | 8.0 % | some concern | not evaluable | moderate | non important | - |
Dry skin TRAE (grade 3-4) | 0.48 [0.04, 5.30] | | < 1 | | 0% | 2 studies (2/-) | 72.5 % | some concern | not evaluable | moderate | non important | - |
Dyspnoea TRAE (grade 3-4) | 1.42 [0.11, 18.62] | | < 1 | | 0% | 2 studies (2/-) | 39.4 % | some concern | not evaluable | moderate | non important | - |
Fatigue TRAE (grade 3-4) | 0.99 [0.05, 18.91] | | < 1 | | 71% | 2 studies (2/-) | 50.4 % | some concern | not evaluable | moderate | non important | - |
Febrile neutropenia TRAE (grade 3-4) | 0.25 [0.04, 1.51] | | < 1 | | 0% | 2 studies (2/-) | 93.4 % | some concern | not evaluable | moderate | non important | - |
Guillain-Barré syndrome TRAE (grade 3-4) | 1.00 [0.06, 16.07] | | < 1 | | 0% | 1 study (1/-) | 49.9 % | NA | not evaluable | | non important | - |
Hepatitis TRAE (grade 3-4) | 1.69 [0.56, 5.15] | | < 1 | | 0% | 3 studies (3/-) | 17.7 % | low | not evaluable | high | non important | - |
Hypersensitivity TRAE (grade 3-4) | 1.43 [0.11, 18.70] | | < 1 | | 0% | 2 studies (2/-) | 39.3 % | some concern | not evaluable | moderate | non important | - |
Hypertension TRAE (grade 3-4) | 2.81 [0.28, 27.87] | | < 1 | | 0% | 2 studies (2/-) | 19.0 % | some concern | not evaluable | moderate | non important | - |
Hyperthyroidism TRAE (grade 3-4) | 1.42 [0.11, 18.62] | | < 1 | | 0% | 2 studies (2/-) | 39.4 % | some concern | not evaluable | moderate | non important | - |
Hypothyroidism TRAE (grade 3-4) | 3.02 [0.31, 29.10] | | < 1 | | 0% | 1 study (1/-) | 17.1 % | NA | not evaluable | | non important | - |
Increase AST TRAE (grade 3-4) | 2.25 [0.20, 25.75] | | < 1 | | 0% | 2 studies (2/-) | 25.8 % | some concern | not evaluable | moderate | non important | - |
Increased ALT TRAE (grade 3-4) | 2.27 [0.20, 25.92] | | < 1 | | 0% | 2 studies (2/-) | 25.6 % | some concern | not evaluable | moderate | non important | - |
Increased lipase level TRAE (grade 3-4) | 2.82 [0.28, 27.94] | | < 1 | | 0% | 2 studies (2/-) | 18.9 % | some concern | not evaluable | moderate | non important | - |
Infusion-related reactions TRAE (grade 3-4) | 0.97 [0.16, 6.00] | | < 1 | | 0% | 3 studies (3/-) | 51.2 % | some concern | not evaluable | moderate | non important | - |
Leucopenia TRAE (grade 3-4) | 0.25 [0.04, 1.51] | | < 1 | | 0% | 2 studies (2/-) | 93.4 % | some concern | not evaluable | moderate | non important | - |
Maculopapular rash TRAE (grade 3-4) | 2.24 [0.25, 19.91] | | < 1 | | 24% | 2 studies (2/-) | 23.5 % | some concern | not evaluable | moderate | non important | - |
Mucosal inflammation TRAE (grade 3-4) | 0.66 [0.18, 2.48] | | < 1 | | 0% | 2 studies (2/-) | 72.9 % | some concern | not evaluable | moderate | non important | - |
Myocarditis TRAE (grade 3-4) | 0.50 [0.02, 14.97] | | < 1 | | 0% | 1 study (1/-) | 65.3 % | NA | not evaluable | | non important | - |
Myositis TRAE (grade 3-4) | 6.04 [0.30, 120.87] | | < 1 | | 0% | 1 study (1/-) | 12.2 % | NA | not evaluable | | non important | - |
Nausea TRAE (grade 3-4) | 1.68 [0.25, 11.08] | | < 1 | | 0% | 2 studies (2/-) | 29.7 % | some concern | not evaluable | moderate | non important | - |
Nephritis TRAE (grade 3-4) | 2.01 [0.07, 59.96] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
Neutropenia TRAE (grade 3-4) | 0.30 [0.02, 5.18] | | < 1 | | 73% | 2 studies (2/-) | 79.3 % | some concern | not evaluable | moderate | non important | - |
Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4) | 0.42 [0.01, 15.25] | | < 1 | | 83% | 2 studies (2/-) | 68.1 % | some concern | not evaluable | moderate | non important | - |
Pancreatitis TRAE (grade 3-4) | 8.07 [0.43, 152.94] | | < 1 | | 0% | 1 study (1/-) | 8.4 % | NA | not evaluable | | non important | - |
Pancytopenia TRAE (grade 3-4) | 0.24 [0.03, 2.14] | | < 1 | | 0% | 2 studies (2/-) | 89.9 % | some concern | not evaluable | moderate | non important | - |
Peripheral neuropathy TRAE (grade 3-4) | 1.43 [0.11, 18.70] | | < 1 | | 0% | 2 studies (2/-) | 39.3 % | some concern | not evaluable | moderate | non important | - |
Peripheral oedema TRAE (grade 3-4) | 1.43 [0.11, 18.70] | | < 1 | | 0% | 2 studies (2/-) | 39.3 % | some concern | not evaluable | moderate | non important | - |
Pneumonia TRAE (grade 3-4) | 1.92 [0.17, 21.31] | | < 1 | | 0% | 2 studies (2/-) | 29.8 % | some concern | not evaluable | moderate | non important | - |
Pneumonitis TRAE (grade 3-4) | 0.97 [0.16, 5.97] | | < 1 | | 0% | 3 studies (3/-) | 51.3 % | some concern | not evaluable | moderate | non important | - |
Pruritic rash TRAE (grade 3-4) | 1.43 [0.11, 18.70] | | < 1 | | 0% | 2 studies (2/-) | 39.3 % | some concern | not evaluable | moderate | non important | - |
Pruritus TRAE (grade 3-4) | 0.96 [0.06, 15.40] | | < 1 | | 0% | 2 studies (2/-) | 51.2 % | some concern | not evaluable | moderate | non important | - |
Pyrexia TRAE (grade 3-4) | 0.96 [0.06, 15.40] | | < 1 | | 0% | 2 studies (2/-) | 51.2 % | some concern | not evaluable | moderate | non important | - |
Rash TRAE (grade 3-4) | 1.64 [0.50, 5.36] | | < 1 | | 48% | 3 studies (3/-) | 20.7 % | some concern | not evaluable | moderate | non important | - |
Sepsis TRAE (grade 3-4) | 0.96 [0.06, 15.40] | | < 1 | | 0% | 2 studies (2/-) | 51.2 % | some concern | not evaluable | moderate | non important | - |
Severe skin reaction TRAE (grade 3-4) | 7.25 [3.06, 17.21] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
Skin exfoliation TRAE (grade 3-4) | 1.43 [0.11, 18.70] | | < 1 | | 0% | 2 studies (2/-) | 39.3 % | some concern | not evaluable | moderate | non important | - |
Stomatitis TRAE (grade 3-4) | 0.58 [0.03, 11.22] | | < 1 | | 73% | 2 studies (2/-) | 63.8 % | some concern | not evaluable | moderate | non important | - |
Thrombocytopenia TRAE (grade 3-4) | 0.48 [0.04, 5.30] | | < 1 | | 0% | 2 studies (2/-) | 72.5 % | some concern | not evaluable | moderate | non important | - |
Vomiting TRAE (grade 3-4) | 0.32 [0.06, 1.58] | | < 1 | | 0% | 2 studies (2/-) | 91.9 % | some concern | not evaluable | moderate | non important | - |
AE (grade 3-4) endpoints 00 |
Acute kidney injury AE (grade 3-4) | 2.01 [0.37, 11.03] | | < 1 | | 0% | 1 study (1/-) | 21.1 % | NA | not evaluable | | non important | - |
Decreased appetite AE (grade 3-4) | 0.83 [0.25, 2.75] | | < 1 | | 0% | 1 study (1/-) | 61.7 % | NA | not evaluable | | non important | - |
Dyspnoea AE (grade 3-4) | 2.52 [0.49, 13.03] | | < 1 | | 0% | 1 study (1/-) | 13.6 % | NA | not evaluable | | non important | - |
Hypertension AE (grade 3-4) | 0.88 [0.67, 1.16] | | < 1 | | 0% | 1 study (1/-) | 81.3 % | NA | not evaluable | | non important | - |
Infusion-related reaction AE (grade 3-4) | 3.03 [0.61, 15.06] | | < 1 | | 0% | 1 study (1/-) | 8.9 % | NA | not evaluable | | non important | - |
Proteinuria AE (grade 3-4) | 0.60 [0.31, 1.18] | | < 1 | | 0% | 1 study (1/-) | 93.0 % | NA | not evaluable | | non important | - |